Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 12/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.33 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.30 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485793 | 0.73 | NQO2 (0.53) | NQO2ALDH1A1TOP1HPGDCASP1 | |
| SCHEMBL548327 | 0.72 | NQO2 (0.49) | NQO2ALDH1A1TOP1HPGDCASP1 | |
| SCHEMBL27631250 | 0.71 | NQO2 (0.44) | NQO2ALDH1A1TOP1HPGDCASP1 | |
| SCHEMBL549273 | 0.70 | NQO2 (0.59) | NQO2ALDH1A1HPGDHSD17B10PRSS1 | |
| SCHEMBL548447 | 0.70 | NQO2 (0.51) | NQO2ALDH1A1TOP1HPGDCASP1 | |
| SCHEMBL549163 | 0.68 | NQO2 (0.40) | NQO2ALDH1A1TOP1HPGDCASP1 | |
| SCHEMBL549298 | 0.68 | NQO2 (0.47) | NQO2ALDH1A1TOP1HPGDCASP1 | |
| SCHEMBL549257 | 0.67 | NQO2 (0.46) | NQO2TDP1 | |
| SCHEMBL548438 | 0.67 | NQO2 (0.50) | NQO2ALDH1A1TOP1HPGDCASP1 | |
| SCHEMBL549333 | 0.65 | NQO2 (0.53) | NQO2ALDH1A1TOP1HPGDCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242059-B1 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIV NORTH CAROLINA (US) | 2007-03-21 | — | — | EP | claimed |
| US-6649652-B2 | Hypotensive agents; hyperglycemic agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-11-18 | — | — | US | claimed |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-15 | — | — | US | claimed |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-14 | — | — | US | claimed |
| EP-1242059-B1 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIV NORTH CAROLINA (US) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | NQO2 396/4885ALDH1A1 976/4885TOP1 2140/4885 |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | NQO2 396/4885ALDH1A1 976/4885TOP1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.